TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07362888: First-in-Human Study of ADCE-B05 in Patients With Advanced Solid Tumors

Sponsor: Adcendo ApS · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 180 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT07362888 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07362888 Rescue Dossier →